{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004062","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.736758+00:00","generated_at":"2026-05-18T23:11:09.073428+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Anika Therapeutics stockholders approve 475,000-share increase in incentive plan","bullets":["Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.","All three Class II director nominees elected: Blanchard, Capper, Larsen.","Advisory say-on-pay vote passed with 8,374,076 for vs 2,529,081 against.","Deloitte & Touche ratified as independent auditor for fiscal 2025.","Annual meeting had 86.13% of voting power present; no opposition to board's solicitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004062","json":"https://secwatch.observer/filing/0001171843-25-004062.json","markdown":"https://secwatch.observer/filing/0001171843-25-004062.md","text":"https://secwatch.observer/filing/0001171843-25-004062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184325004062/0001171843-25-004062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184325004062/f8k_062425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:11:09.073428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}